Skip to main content
Download PDF

The impact of in-hospital cardiac rehabilitation program on medication adherence and clinical outcomes in patients with acute myocardial infarction in the Lazio region of Italy

BMC Cardiovascular Disorders volume 21, Article number: 466 (2021) Cite this article

Abstract

Background

Medication adherence is a recognized key factor of secondary cardiovascular disease prevention. Cardiac rehabilitation increases medication adherence and adherence to lifestyle changes. This study aimed to evaluate the impact of in-hospital cardiac rehabilitation (IH-CR) on medication adherence as well as other cardiovascular outcomes, following an acute myocardial infarction (AMI).

Methods

This is a population-based study. Data were obtained from the Health Information Systems of the Lazio Region, Italy (5 million inhabitants). Hospitalized patients aged ≥ 18 years with an incident AMI in 2013–2015 were investigated. We divided the whole cohort into 4 groups of patients: ST-elevation AMI (STEMI) and non-ST-elevation AMI (NSTEMI) who underwent or not percutaneous coronary intervention (PCI) during the hospitalization. Primary outcome was medication adherence. Adherence to chronic poly-therapy, based on prescription claims for both 6- and 12-month follow-up, was defined as Medication Possession Ratio (MPR) ≥ 75% to at least 3 of the following medications: antiplatelets, β-blockers, ACEI/ARBs, statins. Secondary outcomes were all-cause mortality, hospital readmission for cardiovascular and cerebrovascular event (MACCE), and admission to the emergency department (ED) occurring within a 3-year follow-up period.

Results

A total of 13.540 patients were enrolled. The median age was 67 years, 4.552 (34%) patients were female. Among the entire cohort, 1.101 (8%) patients attended IH-CR at 33 regional sites. Relevant differences were observed among the 4 groups previously identified (from 3 to 17%). A strong association between the IH-CR participation and medication adherence was observed among AMI patients who did not undergo PCI, for both 6- and 12-month follow-up. Moreover, NSTEMI-NO-PCI participants had lower risk of all-cause mortality (adjusted IRR 0.76; 95% CI 0.60–0.95), hospital readmission due to MACCE (IRR 0.78; 95% CI 0.65–0.94) and admission to the ED (IRR 0.80; 95% CI 0.70–0.91).

Conclusions

Our findings highlight the benefits of IH-CR and support clinical guidelines that consider CR an integral part in the treatment of coronary artery disease. However, IH-CR participation was extremely low, suggesting the need to identify and correct the barriers to CR participation for this higher-risk group of patients.

Peer Review reports

Background

Cardiac rehabilitation (CR) is a multidisciplinary intervention, aimed at providing patients with cardiovascular disease with the optimum psychological and physical conditions to prevent their disease from progressing or potentially reversing its course [1]. Several studies have shown that participation in CR after acute myocardial infarction (AMI) is safe and effective to reduce morbidity, mortality, and hospital readmission rates by improving both risk factors’ control and adherence to treatments [2,3,4,5]. Despite these proven benefits, the referral of patients to CR is surprisingly low both in the hospital and in the ambulatory settings [6,7,8]. Given that AMI survivors have a higher incidence rate of readmission or major adverse cardiac events early after discharge as well as lifelong, they need secondary preventive care immediately after onset.

At the same time, medication adherence is a recognized key component of secondary cardiovascular disease prevention. With this regard, international guidelines recommended the combined use of cardioprotective drugs: platelet aggregation inhibitors (antiplatelets), β-blocking agents (β-blockers), angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) as well as statins in combination with ezetimibe and PCSK9-inhibitors [9, 10]. Thus, adherence and persistence to chronic poly-therapy is a key factor in secondary prevention since it is associated with a lower risk of mortality and recurrent events [11,12,13,14,15].

CR programs offer a substantial contribution to achieving and maintaining lifestyle changes and medication adherence [16,17,18,19]. Hence, CR implementation is strongly recommended by clinical guidelines [20,21,22,23]. However, studies on the association between in-hospital CR intervention and adherence to evidence-based (EB) therapies in patients who suffering AMI are scarce in the Italian context. In the real-world, the absence of CR program may result in worse clinical outcomes at long-term follow-up.

The aim of our study was: (1) to evaluate the impact of the application of in-hospital CR program on adherence to chronic polytherapy following AMI and (2) to investigate the long-term effects of CR on three cardiovascular outcomes (all-cause mortality, hospital readmission for cardiovascular and cerebrovascular event, and admission to the emergency department) at three-year follow-up in the setting of the regional health service of Lazio region (Italy).

Methods

Data sources

We conducted a retrospective follow-up study using Italian administrative data. The data were extracted from the Lazio Regional Health Information Systems, which contain, for example, information on hospital admissions, in-hospital cardiac rehabilitation participation, mortality and drug claims. Details of all the individual information systems used in this research have been described in the Additional file 1: Data sources.

Setting and study cohort

This is an observational study based on the population living in the Lazio region, Italy. Using data from the regional hospital information system (HIS), the study included a cohort of all patients discharged from hospitals between 1 January 2013 and 31 December 2015 with a diagnosis of AMI (see Additional file 2: Algorithm for selection of the cohort). In case of multiple hospital admissions, the first admission during the study period was defined as the index admission. ST-elevation AMI (STEMI) patients were identified using ICD-9-CM diagnosis codes 410.xx, excluding 410.7x (non-ST-elevation AMI) and 410.9x (acute AMI, not otherwise specified) in any diagnostic position. Instead, non-ST-elevation AMI (NSTEMI) patients were defined as a diagnosis codes 410.7x, excluding 410.9x. The validity of using this approach for defining AMI in administrative data has been previously documented [24]. Using ICD-9-CM procedure codes, we identified potentially AMI-related treatments provided during the hospital stay, including percutaneous coronary intervention (PCI, codes: 00.66, 36.01, 36.02, 36.05, 36.06, 36.07). Patients aged 18–100 years at discharge were screened for inclusion in the study. Only incident cases of AMI were included: patients with hospitalizations for AMI or related causes (i.e., percutaneous coronary intervention-PCI, bypass, ischemic heart disease, surgery of the heart and great vessels) in the 9 years before index admission were excluded from the analysis. Finally, patients who died or received an outpatient regimen for less than 30 days were excluded, to give all patients the chance to achieve clinical stability and to guarantee a minimum observation period of one month for consistently estimate adherence to polytherapy.

To investigate whether there might be subpopulations in which the effect of CR intervention is stronger, we divided the whole incident cohort into four different groups of AMI patients:

  1. 1.

    STEMI patients who underwent PCI (STEMI-PCI).

  2. 2.

    STEMI patients who did not receive PCI (STEMI-NO-PCI).

  3. 3.

    NSTEMI patients who underwent PCI (NSTEMI-PCI).

  4. 4.

    NSTEMI patients who did not receive PCI (NSTEMI-NO-PCI).

In-hospital cardiac rehabilitation

In the Lazio region there are many CR institutes; during the recovery for an acute episode of AMI, the referral to a CR program was entirely at the discretion of the treating physician. In-hospital cardiac rehabilitation (IH-CR) consists of programs for prevention of deconditioning and recovery of daily activity in the acute phase, as well as supervised exercise therapy and patient education in the early recovery phase.

Patients candidates for access in IH-CR are those with in prolonged unstable conditions, undergoing evaluation for cardiac transplantation or verification of persistence of the indication, patients at high risk of new cardiovascular events and/or clinical instability, patients with a long in-hospital stay discharged after a prolonged stay in intensive care or intensive respiratory/cardiac care; patients with event-related complications, such as stroke, cognitive impairment, renal failure, pulmonary embolism, re-surgery, pleural or pericardial effusions requiring evacuation therapy, infections, complicated wounds, or those with presence or exacerbations of a severe comorbidities. IH-CR, by its multifactorial care structure based on a multidisciplinary team that involves not only the cardiologist but also the social, psychological, and behavioural dimensions of the disease is in a privileged position as regards the approach to the clinical complexity of multimorbidity and frailty.

The participation in IH-CR program was identified through a record linkage procedure between the HIS and the Regional Admission and Discharge Rehabilitation Information System (RAD-R). Therefore, patients who underwent in-hospital cardiac rehabilitation from specialized facilities were classified into the IH-CR group. Patients who did not participate in IH-CR program were classified into the non-IH-CR group. The IH-CR group was defined as patients who participated in IH-CR within 30 days from hospital discharge of the index episode of AMI.

Outcomes

The primary outcome was adherence to EB therapies. Drug exposure information was collected from the regional registry of all drugs dispensed by public and private pharmacies. All drugs in this study were included in the patients’ health care plans and were equally available to all residents, in accordance with the universal health care coverage provided to residents of Italy. Information about prescriptions of antiplatelets (ATC: B01AC04, B01AC05, B01AC06, B01AC22), β-blockers (ATC: C07), ACEI/ARBs (ATC: C09), and statins (ATC: C10AA) were retrieved for all patients. Adherence to medication was measured through the medication possession ratio (MPR), calculated as the number of days of medication supplied during the follow-up based on defined daily doses (DDDs) divided by the number of calendar days in the follow-up. Adherence to chronic poly-therapy was defined as a MPR ≥ 0.75 for at least three of the four evidence-based drugs [15, 25].

Secondary outcomes were (1) all-cause mortality; (2) first hospital readmission due to major adverse cardiovascular and cerebrovascular events (MACCE), defined as a composite of death, recurrent myocardial infarction, ischemic stroke, and hospitalization for heart failure; (3) first admission to the emergency department (ED), occurring within a 3-year follow-up period.

Follow-up

Adherence and persistence to polytherapy after the index event, were evaluated by analyzing prescription patterns during the 6- and 12-month following discharge from the index admission. Follow-up started 30 days after discharge from the index admission. The first 30 days after discharge were used to define exposure, to give all patients the opportunity to start a cardiological rehabilitation program. The end of individual follow-up for measuring drug adherence coincided either with the end of 6-month or 12-month follow-up, the date of death or with the date of all-cause hospitalization whichever came first. Regarding to the secondary outcomes, patients were followed from the 30th day after hospital discharge (the first 30 days after discharge were used to define exposure) to the occurrence of individual events, censoring at the date of non-cardiovascular mortality or the end of 3-year follow-up for MACCE admissions, and censoring at the date of all-cause mortality or the end of 3-year follow-up for admissions to the emergency department.

Statistical analysis

Data are presented as frequencies and percentages for categorical variables and median value (quartile 1–quartile 3) for continuous variables. The impact of IH-CR on adherence to chronic poly-therapy following an AMI was analysed using logistic regression models. Potential confounders were selected based on a priori knowledge [26,27,28], including the following: gender, age and 18 relevant comorbidities retrieved from the hospital records for both the index admission and the two previous years (see Additional file 3: Selection of comorbidities from hospital discharge records). Odds ratios (OR) with the corresponding 95% confidence intervals (95% CI) and p values were computed. We tested the potential interaction between IH-CR participation and sub-cohorts (four distinct groups) of AMI patients by including a cross-product term to each model. The statistical significance of the coefficients for each cross-product term was evaluated using the likelihood-ratio test.

To determine the impact of IH-CR participation on all-cause mortality, hospital readmission due to MACCE, and admission to ED, we used a Poisson regression models (counts divided by person-time). The three secondary outcomes were analyzed individually. All models included the interaction between IH-CR participation and the patient’s subgroup membership and were adjusted for the potential confounders listed in the Additional file 3: Selection of comorbidities from hospital discharge records. Interaction terms were considered statistically significant at P values < 0.10.

Statistical analyses were carried out using Stata software, version 15 (StataCorp.2015. Stata Statistical Software: Release 15. College Station, TX: Stata Corp LP).

Results

Patients’ characteristics and IH-CR participation

The flow chart in Fig. 1 shows the selection process of the study cohort. Of the 28.395 patients discharged from hospital with a first diagnosis of AMI between January 1st 2013 and December 31th 2015, 13.540 (48%) met the inclusion criteria and were enrolled in the present study. Among the entire study population, 1.101 (8.0%) patients began IH-CR at 33 regional sites, during the 30 days following hospital discharge from the index admission. However, the proportion of patients that have participated in IH-CR program strongly changes according to the subgroup of AMI patients identified. Participation in IH-CR ranged from 3 to 17%. Table 1 lists the main characteristics of AMI subpopulations, grouped by IH-CR participation status.

Fig. 1
figure 1

Cohort selection. Exclusion criteria flow chart

Full size image
Table 1 Clinical and procedural characteristics of AMI patients grouped by IH-CR status
Full size table

IH-CR participants were more frequently male, slightly older, and had a greater burden of comorbidities and interventional procedures. In fact, the participants were more likely to have a history of heart failure, conduction disorders or arrhythmias or other cardiac diseases, were more likely to be seen with cerebrovascular diseases or more likely to be treated with other operations on heart and pericardium, compared with those who did not participate in IH-CR program. However, regarding these percentages, more or less evident differences can be observed across the 4 subgroups of patients. In addition, the median length of IH-CR stay ranged between 20 to 22 days.

Impact of IH-CR on adherence to chronic polytherapy

The adherence to EB medications by AMI subpopulations and IH-CR participation status is reported in Table 2. Overall, 44% and 51% of the patients were deemed adherent to polytherapy during the 6-and 12-month follow-up. Subgroup analyses revealed that STEMI-PCI patients were characterised by the highest adherence, for both 6-and 12-month follow-up (52% and 60%, respectively), followed by NSTEMI-PCI patients (49% and 56%). The adherence to therapies decreased markedly, for both STEMI and NSTEMI, considering those patients who did not undergo PCI: (31% and 35% for STEMI), (29% and 33% for NSTEMI patients).

Table 2 Adherence to chronic poly-therapy at 6- and 12-month follow-up by AMI groups
Full size table

Using the logistic models with term-interaction between IH-CR participation and 4 subpopulations of AMI patients, the impact of IH-CR participation on adherence to chronic poly-therapy was determined. The “global” interaction term was statistically significant (p value < 0.001), for both 6- and 12-month follow-up. As visualized in Fig. 2, the effect of cardiac rehabilitation on adherence to medications differed considerably between subpopulation groups. IH-CR participation was associated with a statistically significant increase in adherence to chronic poly-therapy at 6-month (OR 1.63; 95% CI 1.06–2.50; p value: 0.02) for STEMI-NO-PCI patients, and this improvement was also maintained at 12-month follow-up assessment (OR 1.63; 95% CI 1.07–2.47; p value: 0.02). A similar but even stronger effect was observed for NSTEMI-NO-PCI patients, who attended the IH-CR program compared with non-attenders at 6-month (OR 1.85; 95% CI 1.51–2.27; p value < 0.001) and at 12-month follow-up assessment (OR 2.13; 95% CI 1.74–2.60; p value: < 0.001). In contrast, the effect of IH-CR intervention on adherence was not observed in STEMI-PCI group (OR 0.90; 95% CI 0.70–1.16; p value: 0.427), (OR 0.83; 95% CI 0.65–1.07; p value: 0.157), at 6-and 12-month follow-up, respectively. A similar non-significant trend was observed among NSTEMI-PCI patients.

Fig. 2
figure 2

The effect of IH-CR on adherence to poly-therapy at 6-and 12-month follow-up, by AMI groups

Full size image

Impact of IH-CR on the occurrence of secondary outcomes

During the 3-year follow-up, there were 1.635 all-cause deaths in our population cohort. In addition, admission to emergency department was noted in 6.928 patients, while hospital readmission due to MACCE was noted in 3.302 patients. The 3-year follow-up rates of these outcomes were 12%, 51%, and 24%, respectively. As regards the Poisson regression models, the global interaction term between IH-CR participation and the patient’s subgroup membership was statistically significant (p value < 0.001) for each of the three secondary outcomes. As shown in Fig. 3, the participation in cardiac rehabilitation would appear to have a “protective effect” on the occurrence of the adverse secondary outcomes, for three out of the four sub-cohorts identified. Specifically, for the NSTEMI-NO-PCI group, this protective effect of IH-CR was statistically significant for all three adverse outcomes. Incidence rates of all-cause mortality, hospital readmission due to MACCE and admission to ED were significantly lower in the IH-CR participants than in the non-participants. The relative risks were 0.76 (95% CI 0.60–0.95), 0.78 (95% CI 0.65–0.94), and 0.80 (95% CI 0.70–0.91), respectively.

Fig. 3
figure 3

The effect of IH-CR on incidence of secondary outcomes at 3-year follow-up, by AMI groups

Full size image

Surprisingly, in the first group of AMI patients (STEMI-PCI), the effect of IH-CR participation on the occurrence of secondary outcomes switched from protective factor to risk factor. We found for this specific group, significantly higher incidence rates for all secondary outcomes, among patients who participated at IH-CR compared with non-participants.

Discussion

This study provides novel ‘real world’ data on the referral and impact of in-hospital cardiac rehabilitation programs in patients suffering AMI. The study involved more than 13.000 patients admitted to hospitals in the Lazio region of Italy between 2013 and 2015.

The study results showed that IH-CR participation rates are alarmingly low, ranging from 3 to 17% in relation to the groups of the AMI population identified. The highest IH-CR referral rate were observed for STEMI and NSTEMI patients who did not receive PCI during the index hospitalization. Overall, we found that only 1.101 patients (8%) started cardiac rehabilitation program within 30 days from the hospital discharge following an AMI.

As evidenced by the results of this study, IH-CR referral rates have been very low in comparison with other E-B treatments. Previous investigations from several states reported an average referral rate of 30% in Canada, the USA, and the UK, and a little higher at 50% in the rest of Europe [29]. Differences in the organization of health care services and delivery systems between countries and across hospitals may explain, most probably, this variability. Moreover, there are also differences in referral rates between European countries, but little is known, in literature, about the real motivations for underuse of cardiac rehabilitation in different EU countries and hospitals [10, 30]. However, these current low rates of participations in IH-CR programs are wholly inadequate and deprive a large proportion of patients with cardiovascular disease of a safe and effective intervention in reducing disease-related disability, as well as hospital readmission and long-term mortality. There are several reasons for this inadequate use of CR. First of all, the lack of a hospital system that automatically associates the rehabilitation program with each eligible patient, without the intermediation of a physician or health care staff. In fact, previous studies suggested that the most important predictor, is exactly the lack of CR referral at hospital discharge [31].

Sometimes, it may be that patients do not receive enough information and encouragement to participate in CR by their physician or other health professionals. However, physicians certainly need to take into consideration many factors when giving a CR referral: a patient could be too old or frail to benefit from CR, or conversely, too healthy and may not need this intervention. Last but not least, CR regimes are not standardized across countries regarding duration (3/6 weeks or 12/16 weeks), setting (in-hospital or ambulatory), and main goal of therapy (exercised based or comprehensive recommending). In Italy, there are no top-down standards or guidelines regarding the scope of services in IH-CR. The gold standard of care refers to the guidelines drawn up from the scientific societies. The need for a national clinical register in Italy, which supports the standardization of interventions has been repeatedly advanced by the scientific community [32]. The procedures, the personnel, and modalities necessary for carrying out the activities that can be defined as "rehabilitation intervention", have been also specified. However, at least in the Lazio region there are no steering documents that make the standard of care in CR mandatory [33]. Moreover, this work increases knowledge and awareness that, even in the most advanced interventional cardiology contexts, where networks hub and spoke for acute myocardial infarction have already been developed for two decades, post-acute care is still very lacking. In fact, consistent with the results of other investigations [26,27,28, 34] in the present study we found that evidence-based pharmacological therapies for secondary prevention after AMI were under-used (overall, 44% and 51% of the patients were deemed adherent to poly-therapy at 6-and 12-month, respectively).

Our findings showed a differential impact of cardiac rehabilitation program on polytherapy adherence both at 6-and 12-month follow-up assessment. The magnitude of this impact depending on the different groups of AMI patients considered, which are related to IH-CR participation. Principally, there would seem to be a strong different impact between patients who underwent or not PCI, regardless of the AMI diagnosis, during the index hospitalization. In fact, during the 6-month follow-up, after adjusting for potential confounders, STEMI-NO-PCI and NSTEMI-NO-PCI patients who started IH-CR program were, 63% and 85% respectively, more likely to be adherent as compared with non-participants. Interestingly, polytherapy adherence was maintained for STEMI-NO-PCI participant patients (63%), and even increased for NSTEMI-NO-PCI patients at 12-month follow-up, suggesting that patients who could not undergo revascularization by coronary angioplasty may have been more often referred to IH-CR than those who received coronary angioplasty. Likewise, the rehabilitation intervention results in a greater adherence to drug therapy. Among NSTEMI-NO-PCI patients who participated in IH-CR were more than twice as likely to be adherent to E-B drugs (OR 2.13; 95% CI 1.74–2.60; p value: < 0.001). Of note, estimates were adjusted for all variables identified as potential confounders such as age, gender, and 18 comorbidities listed in the Additional file 3: Selection of comorbidities from hospital discharge records. By contrast, the effect of IH-CR intervention on adherence was not observed in the other two subgroups of AMI patients (STEMI and NSTEMI) who underwent PCI during the index event. This result may be partially due to the fact that AMI patients who underwent a primary percutaneous coronary intervention have already been inserted in specific care pathways. In fact, these two groups of patients, regardless of IH-CR participation status, showed the highest adherence, for both 6-and 12-month follow-up (52% and 60% for STEMI; 49% and 56% for NSTEMI patients). Therefore, the beneficial effect of IH-CR treatment on medication adherence could be attenuated by the fact that AMI patients who underwent revascularization had been more carefully monitored and made aware of the long-term benefits generated by a continuous and persistent drug treatment.

The evidence of greater effect of IH-CR on the adherence to long-term evidence-based drugs in more complex groups, i.e., in patients who have had an acute coronary event but not revascularized, reinforces the concept that rehabilitation intervention is extremely relevant from a prognostic point of view. Non-revascularized patients with multiple comorbidities are recognized as those with the highest residual cardiovascular risk. Numerous clinical, epidemiological and intervention studies confirm this finding. In Italy, data from the National Outcomes Program (NOP) of 2016 show a reduction in mortality at 30 days from admission for acute myocardial infarction (AMI), from 10.4% in 2010 to 9.0% in 2015. An Italian retrospective study based on the administrative database of hospital discharge forms (HDF) examined over one million patients admitted for AMI from 2001 to 2011 in all Italian hospitals, evaluating the mortality and hospital readmission rates at 30 days and at 1 year and re-hospitalization for all causes. While the mortality rate at the index event declined the rate of fatal readmission at 1 year increased from 4.75 to 5.28% (p = 0.0019) [35]. It thus emerges that, while the in-hospital management of ACS has shown great progress in terms of its diagnostic-therapeutic efficacy, post-discharge care has not had a positive impact on the post-discharge prognosis of ACS. This is in part attributable to the inadequacy and poor application of appropriate cardiac care pathways for the post-discharge period, based on different care needs modelled according to the individual patient’s level of risk. A high residual risk of MACCE recurrence can be detected both by clinical factors, such as diabetes mellitus, renal failure, peripheral artery disease, a history of angina or previous AMI, and by anatomical/surgical factors, such as the presence of multivessel disease, especially if treated with incomplete revascularization, or no revascularization at all. Elderly age is an associated high-risk factor included in the above comorbidities. A recent Italian study, based on HDF administrative data, analysed the risk of thrombosis in patients admitted in the years 2009 and 2010. At multivariate analysis, most of the factors defining high thrombotic risk were independent predictors of 5-year mortality. The effect of "thrombotic risk" on mortality resulted to be time-dependent with a hazard ratio (HR) that strongly increased in the first two years of follow-up, then slowly levelled out in the following years to reach a plateau around the 5th year. This finding confirms not only the importance of targeting intensive prevention therapeutic strategies in the period immediately following ACS but points to the need for long-term secondary prevention programs in subgroups of high-risk patients [13]. Intervention studies have confirmed this epidemiological trend as regards dual antiplatelet therapy [36,37,38], LDL target [39, 40] and even low-dose anticoagulation in the more recent COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies) [41]. In this context, therefore, adherence to evidence-based therapy, as well as implementation of new secondary prevention pharmacological strategies in patients at very high residual risk plays a fundamental role. Unfortunately, despite the evidence, as also evidenced by the results of this research, the adherence to pharmacological therapies after an acute event is still far from optimal.

Moreover, the present study investigated the long-term effects of IH-CR intervention on all-cause mortality, hospital readmission due to MACCE, and admission to ED at 3-year follow-up. As previously mentioned, the participation in IH-CR had a “protective effect” on the occurrence of these three adverse secondary outcomes, for three out of the four subpopulations identified. However, this protective effect was statistically significant only for NSTEMI-NO-PCI patients. The study results showed that IH-CR participation, was associated with 24% of risk reduction of mortality (IRR 0.76; 95% CI 0.60–0.95; p value: 0.021), 22% of MACCE readmission (IRR 0.78; 95% CI 0.65–0.94; p value: 0.011), and 20% of ED admission (IRR 0.80; 95% CI 0.70–0.91; p value: 0.001). Much of this effect is probably due to the increase in adherence to evidence-based therapies. Our findings are consistent with the results of other investigations that reported a relationship between CR participation and risk reduction for AMI patients [42,43,44]. In addition, meta-analyses suggested that CR participation can reduce all-cause mortality by 15–28% for AMI patients [45, 46], confirming our results. We should be pointed out how NSTEMI-NO-PCI patients had the highest percentage of patients who participated in IH-CR intervention (17%) compared to the other AMI subgroups. Moreover, in absolute terms, patients with a diagnosis of NSTEMI who did not undergo PCI, represented the 50% of all AMI patients that have participated in IH-CR program in this research.

Rather, we found that all these secondary outcomes tended to be higher in the IH-CR group for STEMI-PCI patients. However, based on the factors showed in Table 1, it appears evident a different severity of patient’s condition who participated or not to IH-CR program in this specific subgroup of population. In fact, IH-CR participants were more likely to have a history of heart failure (29% vs. 7%), conduction disorders or arrhythmias (32% vs. 19%), and were more likely to be treated with other operations on heart and pericardium (11% vs. 1%), compared with those who did not participate in IH-CR program. Consequently, all-cause mortality tended to be higher in the IH-CR group (17% vs. 6%).

Notable, the median follow-up time to death for patients who participated in IH-CR was 384 days (IQR 161–688) versus 603 days (IQR 301–822) for those who did not participate. For the above-mentioned reasons, it is reasonable to expect a strong disparity in the characteristics of patients who did or did not participate in IH-CR even for all variables that cannot be measured. Although we evaluated all available potential factors to adjust patient deviation, we could not adjust for imbalance in unmeasured confounders. Therefore, most likely the lack of more detailed data (e.g., ejection fraction, history of smoking, BMI, number of sessions completed, exercise capacity, vital sign, functional status, frailty, or social risk factors) has caused unmeasured confounding resulting in higher incidence rates for secondary outcomes, among STEMI-PCI patients who participated in cardiac rehabilitation compared with non-participants.

Strengths and limitations of the study

A strength of the study is the possibility to integrate different Health Information Systems of the Lazio region of Italy, in order to achieve a well-defined (e.g., chronological, demographical, clinical) healthcare-related patient profile and to involve a large number of patients. The robustness of the applied statistical methodologies, a population study design and a long-term follow-up are the major strengths. A weakness of this study is that the results derived from a single region of Italy, so may not be generalizable to other contexts due to differences in healthcare policies. Moreover, a misclassification of drug utilization may have occurred because in our database the prescribed daily doses were not known, and the defined daily doses were used as the dosage assumption to measure adherence to polytherapy [47, 48]. In addition, we only used data from RAD-R for the definition of study’s exposure (participation in cardiac rehabilitation). This information system collects data about patients referred to CR specialized facilities from hospital acute care centers and may not reflect the experience of other cardiac rehabilitation centers. Therefore, the IH-CR participation proportion may have underestimated. Finally, the lack of more detailed clinical data may have caused unmeasured confounding, despite all available potential confounders were considered to adjust for differences in characteristics of patients.

Conclusions

This research offers a portrait of the “real world” of clinical practice concerning patients after an acute myocardial infarction. We revealed the association between IH-CR and clinical outcomes among subgroups of AMI patients. IH-CR participation was strongly associated to a significant improvement of adherence to evidence-based therapies both at 6- and 12-month follow-up among AMI patients who did not undergo PCI during the index hospitalization. Moreover, participation in IH-CR program was related to significant risk reduction of all-cause mortality, hospital readmission due to cardiovascular and cerebrovascular events, and admission to the emergency department during 3-year follow-up period among NSTEMI patients who did not undergo PCI.

These findings highlight the benefits of IH-CR, even in an unfavourable context due to the smallness of referral of IH-CR patients and support the clinical practise guidelines that consider cardiac rehabilitation an integral part in the treatment of coronary artery disease. AMI patients should be referred to IH-CR program, as soon as possible after the acute event, especially for those who did not received PCI during the hospitalization, and for this reason probably will not be able to benefit from a dedicated care pathway.

However, underutilization of CR is an established worldwide issue, despite its known health benefits. Referral rates urgently need improvement, and national target CR quality improvement interventions should be supported.

Availability of data and materials

The datasets analyzed during the current study are not publicly available due to privacy issues but are available from the corresponding author on reasonable request.

Abbreviations

CR:

Cardiac rehabilitations

AMI:

Acute myocardial infarction

IH-CR:

In-hospital cardiac rehabilitation

STEMI:

ST-elevation AMI

NSTEMI:

Non-ST-elevation AMI

PCI:

Percutaneous coronary intervention

MACCE:

Major adverse cardiovascular and cerebrovascular events

ED:

Emergency department

ACEIs:

Angiotensin converting enzyme inhibitors

ARBs:

Angiotensin receptor blockers

EB:

Evidence-based

HIS:

Hospital Information Systems

RAD-R:

Regional Admission and Discharge Rehabilitation Information System

HEIS:

Healthcare Emergency Information System

MIS:

Mortality Information System

MPR:

Medication possession ratio

DDDs:

Defined daily doses

IQR:

Interquartile range

OR:

Odds ratio

95%CI:

95% Confidence intervals

IRR:

Incidence rate ratio

References

  1. McMahon SR, Ades PA, Thompson PD. The role of cardiac rehabilitation in patients with heart disease. Trends Cardiovasc Med. 2017;27:1–5.

    Article  Google Scholar 

  2. Goel K, Lennon RJ, Tilbury RT, Squires RW, Thomas RJ. Impact of cardiac rehabilitation on mortality and cardiovascular events after percutaneous coronary intervention in the community. Circulation. 2011;123:2344–52.

    Article  PubMed  Google Scholar 

  3. Lawler PR, Filion KB, Eisenberg MJ. Efficacy of exercise-based cardiac rehabilitation post-myocardial infarction: a systematic review and metaanalysis of randomized controlled trials. Am Heart J. 2011;162:571–84.

    Article  PubMed  Google Scholar 

  4. Dunlay SM, Pack QR, Thomas RJ, Killian JM, Roger VL. Participation in cardiac rehabilitation, readmissions, and death after acute myocardial infarction. Am J Med. 2014;127:538–46.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Doll JA, Hellkamp A, Thomas L, Ho PM, Kontos MC, Whooley MA, Boyden TF, Peterson ED, Wang TY. Effectiveness of cardiac rehabilitation among older patients after acute myocardial infarction. Am Heart J. 2015;170:855–64.

    Article  PubMed  Google Scholar 

  6. Doll JA, Hellkamp A, Ho PM, Kontos MC, Whooley MA, Peterson ED, Wang TY. Participation in cardiac rehabilitation programs among older patients after acute myocardial infarction. JAMA Intern Med. 2015;175:1700–2.

    Article  PubMed  Google Scholar 

  7. Brown TM, Hernandez AF, Bittner V, Cannon CP, Ellrodt G, Liang L, Peterson ED, Pina IL, Safford MM, Fonarow GC. Predictors of cardiac rehabilitation referral in coronary artery disease patients: findings from the American Heart Association’s Get With The Guidelines Program. J Am Coll Cardiol. 2009;54:515–21.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Mazzini MJ, Stevens GR, Whalen D, Ozonoff A, Balady GJ. Effect of an American Heart Association Get With the Guidelines program–based clinical pathway on referral and enrollment into cardiac rehabilitation after acute myocardial infarction. Am J Cardiol. 2008;101:1084–7.

    Article  PubMed  Google Scholar 

  9. Piepoli MF, Hoes AW, Agewall S, et al. European guidelines on cardiovascular disease prevention in clinical practice. G Ital Cardiol. 2017;18:547–612.

    Google Scholar 

  10. National Institute for Clinical Excellence. Secondary prevention in primary and secondary care for patients following a myocardial infarction. NICE guidelines [CG172]. Published date: November 2013.

  11. Choudhry NK, Glynn RJ, Avorn J, et al. Untangling the relationship between medication adherence and post-myocardial infarction outcomes: medication adherence and clinical outcomes. Am Heart J. 2014;167:51-8.e5.

    Article  PubMed  Google Scholar 

  12. Jernberg T, Hasvold P, Henriksson M, et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36:1163–70.

    Article  PubMed  Google Scholar 

  13. Mureddu GF, Greco C, Rosato S, D’Errigo P, De Luca L, Badoni G, Faggiano P, Seccareccia F. High thrombotic risk increases adverse clinical events up to 5 years after acute myocardial infarction: a nationwide retrospective cohort study. Monaldi Arch Chest Dis. 2019;89:1166.

    Article  Google Scholar 

  14. Gislason GH, Rasmussen JN, Abildstrøm SZ, Gadsbøll N, Buch P, Friberg J, Rasmussen S, Køber L, Stender S, Madsen M, Torp-Pedersen C. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J. 2006;27(10):1153–8.

    Article  CAS  PubMed  Google Scholar 

  15. Kirchmayer U, Di Martino M, Agabiti N, et al. Effect of evidence-based drug therapy on long-term outcomes in patients discharged after myocardial infarction: a nested case–control study in Italy. Pharmacoepidemiol Drug Saf. 2013;22:649–57.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol. 2011;58:2432–46.

    Article  PubMed  Google Scholar 

  17. Anderson L, Oldridge N, Thompson DR, et al. Exercise-based cardiac rehabilitation for coronary heart disease. J Am Coll Cardiol. 2016;67:1–12.

    Article  PubMed  Google Scholar 

  18. McMahon SR, Ades PA, Thompson PD. The role of cardiac rehabilitation in patients with heart disease. Trends Cardiovasc Med. 2017;27:420–5.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Ho PM, Lambert-Kerzner A, Carey EP, et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial. JAMA Intern Med. 2014;174:186–93.

    Article  PubMed  Google Scholar 

  20. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016; 37 (29): 2315–81.

  21. Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of cardiology (ESC). Eur Heart J. 2018;39:119–77.

    Article  PubMed  Google Scholar 

  22. JCS Joint Working Group. Guidelines for rehabilitation in patients with cardiovascular disease (JCS 2012). Circ J. 2014;78:2022–93.

    Article  Google Scholar 

  23. Gilboy N, Tanabe T, Travers D, Rosenau AM (2011) Emergency severity index (ESI): a triage tool for emergency department care, version 4. Implementation handbook 2012 edn. AHRQ publication no. 12-0014. Agency for Healthcare Research and Quality, Rockville, MD (ISBN 978-1-58763-416-1).

  24. McCormick N, Lacaille D, Bhole V, Avina-Zubieta JA. Validity of myocardial infarction diagnoses in administrative databases: a systematic review. PLoS ONE. 2014;9(3):e92286.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  25. Di Martino M, Alagna M, Cappai G, et al. Adherence to evidence-based drug therapies after myocardial infarction: is geographic variation rcyelated to hospital of discharge or primary care providers? A cross-classified multilevel design. BMJ Open. 2016;6(4):e010926.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119:3028–35.

    Article  PubMed  Google Scholar 

  27. Mathews R, Wang TY, Honeycutt E, et al. TRANSLATE-ACS Study Investigators: persistence with secondary prevention medications after acute myocardial infarction: insights from the TRANSLATE-ACS study. Am Heart J. 2015;170:62–9.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Soldati S, Di Martino M, Castagno D, Davoli M, Fusco D. In-hospital myocardial infarction and adherence to evidence-based drug therapies: a real-world evaluation. BMJ Open. 2021;11(2):e042878. https://doi.org/10.1136/bmjopen-2020-042878.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Aragam KG, Moscucci M, Smith DE, Riba AL, Zainea M, Chambers JL, Share D, Gurm HS. Trends and disparities in referral to cardiac rehabilitation after percutaneous coronary intervention. Am Heart J. 2011;161:544-551.e2.

    Article  PubMed  Google Scholar 

  30. Dalal HM, Wingham J, Palmer J, Taylor R, Petre C, Lewin R. Why do so few patients with heart failure participate in cardiac rehabilitation? A cross-sectional survey from England, Wales and Northern Ireland. BMJ Open. 2012;2:000787.

    Article  Google Scholar 

  31. Aragam KG, Dai D, Neely ML, Bhatt DL, Roe MT, Rumsfeld JS, Gurm HS. Gaps in referral to cardiac rehabilitation of patients undergoing percutaneous coronary intervention in the United States. J Am Coll Cardiol. 2015;65:2079–88.

    Article  PubMed  Google Scholar 

  32. Mureddu GF. Secondary cardiovascular prevention in clinical practice: what do we need today? Monaldi Arch Chest Dis. 2019. https://doi.org/10.4081/monaldi.2019.1160.

    Article  PubMed  Google Scholar 

  33. Fattirolli F, Bettinardi O, Angelino E, et al. What constitutes the ‘MinimalCare’ interventions of the nurse, physiotherapist, dietician and psychologist in Cardiovascular Rehabilitation and secondary prevention: a position paper from the Italian Association for Cardiovascular Prevention, Rehabilitation and Epidemiology. Eur J Prev Cardiol. 2018;00:1–12.

    Google Scholar 

  34. Kirchmayer U, Agabiti N, Belleudi V, et al. Socio-demographic differences in adherence to evidence-based drug therapy after hospital discharge from acute myocardial infarction: a population-based cohort study in Rome, Italy. J Clin Pharm Ther. 2012;37:37–44.

    Article  CAS  PubMed  Google Scholar 

  35. Greco C, Rosato S, D’Errigo P, Mureddu GF, Lacorte E, Seccareccia F. Trends in mortality and heart failure after acute myocardial infarction in Italy from, 2001 to 2011. Int J Cardiol. 2015;184:115–21.

    Article  PubMed  Google Scholar 

  36. Bonaca MP, Bhatt DL, Cohen M, et al. PEGASUS-TIMI 54 Steering Committee and Investigators: long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791–800.

    Article  PubMed  Google Scholar 

  37. Bonaca MP, Storey RF, Theroux P, et al. Efficacy and safety of ticagrelor over time in patients with prior MI in PEGASUS-TIMI 54. J Am Coll Cardiol. 2017;70:1368–75.

    Article  CAS  PubMed  Google Scholar 

  38. Mauri L, Kereiakes DJ, Yeh RW, et al. DAPT study investigators: twelve or 30 months of dual antiplatelet therapy after drug eluting stents. N Engl J Med. 2014;371:2155–66.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  39. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR. For the FOURIER steering committee and investigators*Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:18.

    Article  Google Scholar 

  40. Steg G et al. ODYSSEY outcomes: evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with Alirocumab trial. ACC 2018.

  41. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O’Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Störk S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz F, Chen E, Leong D, Yusuf S. For the COMPASS investigators (cardiovascular outcomes for people using anticoagulation strategies). N Engl J Med. 2017;377:1319–30.

    Article  CAS  PubMed  Google Scholar 

  42. Doimo S, Fabris E, Piepoli M, et al. Impact of ambulatory cardiac rehabilitation on cardiovascular outcomes: a long-term follow-up study. Eur Heart J. 2019;21(40):678–85.

    Article  Google Scholar 

  43. Scalvini S, Grossetti F, Paganoni AM, et al. Impact of in-hospital cardiac rehabilitation on mortality and readmissions in heart failure: a population study in Lombardy, Italy, from 2005 to 2012. Eur J Prev Cardiol. 2019;26:808–17.

    Article  PubMed  Google Scholar 

  44. Griffo R, Ambrosetti M, Tramarin R, et al. Effective secondary prevention through cardiac rehabilitation after coronary revascularization and predictors of poor adherence to lifestyle modification and medication: cy4results of the ICAROS survey. Int J Cardiol. 2013;167:1390–5.

    Article  PubMed  Google Scholar 

  45. Martin B-J, Hauer T, Arena R, Austford LD, Galbraith PD, Lewin AM, Knudtson ML, Ghali WA, Stone JA, Aggarwal SG. Cardiac rehabilitation attendance and outcomes in coronary artery disease patients. Circulation. 2012;126:677–87.

    Article  PubMed  Google Scholar 

  46. Clark AM, Hartling L, Vandermeer B, McAlister FA. Meta-analysis: secondary prevention programs for patients with coronary artery disease. Ann Intern Med. 2005;143:659–72.

    Article  PubMed  Google Scholar 

  47. World Health Organization, Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment 2020. Oslo, Norway, 2019.

  48. Grimmsmann T, Himmel W. Discrepancies between prescribed and defined daily doses: a matter of patients or drug classes? Eur J Clin Pharmacol. 2011;67:847–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Department of Epidemiology, Lazio Regional Health Service, Rome, Italy

    Salvatore Soldati, Mirko Di Martino, Alessandro Cesare Rosa, Danilo Fusco & Marina Davoli

  2. Department of Cardiovascular Diseases, S. Giovanni-Addolorata Hospital, Rome, Italy

    Gian Francesco Mureddu

Authors
  1. Salvatore Soldati
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mirko Di Martino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alessandro Cesare Rosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Danilo Fusco
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marina Davoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gian Francesco Mureddu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SS contributed to the design of the study, the acquisition of data from the Lazio regional health information systems, the analysis of data and the statistical methodology required for the analytic modelling, the interpretation of results, and the writing of the article. MDM contributed to the design of the study, the statistical methodology required for the analytic modelling, the interpretation of results, and the writing of the article. ACR contributed to the design of the study, the analysis of data and the interpretation of the results. MD and DF contributed to the design of the study, and the critical revision of the paper for important intellectual content, and they have given their final approval of the version submitted for publication. GFM contributed to the concept and design of the study, the clinical interpretation of results, and the writing of the article. All authors agree to be accountable for all aspects of the work and ensure that questions related to the accuracy or integrity of any part of the work were appropriately investigated and resolved. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Mirko Di Martino.

Ethics declarations

Ethics approval and consent to participate

Research was performed in accordance with the Declaration of Helsinki and was approved by ‘Lazio Region Ethics Committee' (approval number: 383/CE Lazio 1). Consent to participate is not required. This is a retrospective, observational, population-based study. Data were collected from Health Information Systems of the Lazio Region, Italy. The Department of Epidemiology is legitimised by the “Lazio Region Committee” in managing and analysing data from the regional Health Information Systems for epidemiological purposes. Patient data were completely anonymized, and results were reported in aggregate form only.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Table S1.

Data sources.

Additional file 2: Table S2.

Algorithm for selection of the cohort.

Additional file 3: Table S3.

Selection of comorbidities from hospital discharge records.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Soldati, S., Di Martino, M., Rosa, A.C. et al. The impact of in-hospital cardiac rehabilitation program on medication adherence and clinical outcomes in patients with acute myocardial infarction in the Lazio region of Italy. BMC Cardiovasc Disord 21, 466 (2021). https://doi.org/10.1186/s12872-021-02261-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12872-021-02261-6

Keywords

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us